Drug Profile
Malaria vaccine - GSK/Crucell
Alternative Names: Ad35-CS, RTS,S/AS; Ad35.CS.01; Malaria vaccine - Crucell/GSK; Replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01) - CrucellLatest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Crucell; GlaxoSmithKline
- Developer Crucell; GSK
- Class Antimalarials; Parasitic vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 09 Sep 2015 No recent reports on development identified - Phase-II for Malaria (Prevention, In volunteers) in USA (IM)
- 06 Sep 2013 Isconova is now called Novavax AB
- 22 Aug 2013 Isconova has been acquired by Novavax